Effects of levodopa on pulmonary function in Parkinson's disease.
Identifieur interne : 000162 ( Ncbi/Merge ); précédent : 000161; suivant : 000163Effects of levodopa on pulmonary function in Parkinson's disease.
Auteurs : B. Herer [France] ; I. Arnulf ; B. HoussetSource :
- Chest [ 0012-3692 ] ; 2001.
English descriptors
- KwdEn :
- Aged, Aged, 80 and over, Airway Obstruction (complications), Antiparkinson Agents (pharmacology), Cross-Over Studies, Double-Blind Method, Female, Humans, Levodopa (pharmacology), Male, Middle Aged, Parkinson Disease (complications), Parkinson Disease (physiopathology), Respiratory Function Tests, Respiratory Mechanics (drug effects), Spirometry.
- MESH :
- chemical , pharmacology : Antiparkinson Agents, Levodopa.
- complications : Airway Obstruction, Parkinson Disease.
- drug effects : Respiratory Mechanics.
- physiopathology : Parkinson Disease.
- Aged, Aged, 80 and over, Cross-Over Studies, Double-Blind Method, Female, Humans, Male, Middle Aged, Respiratory Function Tests, Spirometry.
Abstract
Upper-airway obstruction (UAO) may be present in patients with Parkinson's disease (PD), and its reversibility after levodopa therapy has been suggested. To investigate the effects of oral intake of levodopa on pulmonary function and UAO criteria in patients with PD, we studied 22 patients with PD.
PubMed: 11171713
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001261
- to stream PubMed, to step Curation: 001220
- to stream PubMed, to step Checkpoint: 001220
Links to Exploration step
pubmed:11171713Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effects of levodopa on pulmonary function in Parkinson's disease.</title><author><name sortKey="Herer, B" sort="Herer, B" uniqKey="Herer B" first="B" last="Herer">B. Herer</name><affiliation wicri:level="1"><nlm:affiliation>Service de Pneumologie, Centre Médical de Forcilles, Férolles-Attilly, France. HBherer@aol.com</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de Pneumologie, Centre Médical de Forcilles, Férolles-Attilly</wicri:regionArea><wicri:noRegion>Férolles-Attilly</wicri:noRegion><wicri:noRegion>Férolles-Attilly</wicri:noRegion></affiliation></author><author><name sortKey="Arnulf, I" sort="Arnulf, I" uniqKey="Arnulf I" first="I" last="Arnulf">I. Arnulf</name></author><author><name sortKey="Housset, B" sort="Housset, B" uniqKey="Housset B" first="B" last="Housset">B. Housset</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2001">2001</date><idno type="RBID">pubmed:11171713</idno><idno type="pmid">11171713</idno><idno type="wicri:Area/PubMed/Corpus">001261</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001261</idno><idno type="wicri:Area/PubMed/Curation">001220</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001220</idno><idno type="wicri:Area/PubMed/Checkpoint">001220</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001220</idno><idno type="wicri:Area/Ncbi/Merge">000162</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Effects of levodopa on pulmonary function in Parkinson's disease.</title><author><name sortKey="Herer, B" sort="Herer, B" uniqKey="Herer B" first="B" last="Herer">B. Herer</name><affiliation wicri:level="1"><nlm:affiliation>Service de Pneumologie, Centre Médical de Forcilles, Férolles-Attilly, France. HBherer@aol.com</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de Pneumologie, Centre Médical de Forcilles, Férolles-Attilly</wicri:regionArea><wicri:noRegion>Férolles-Attilly</wicri:noRegion><wicri:noRegion>Férolles-Attilly</wicri:noRegion></affiliation></author><author><name sortKey="Arnulf, I" sort="Arnulf, I" uniqKey="Arnulf I" first="I" last="Arnulf">I. Arnulf</name></author><author><name sortKey="Housset, B" sort="Housset, B" uniqKey="Housset B" first="B" last="Housset">B. Housset</name></author></analytic><series><title level="j">Chest</title><idno type="ISSN">0012-3692</idno><imprint><date when="2001" type="published">2001</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Airway Obstruction (complications)</term><term>Antiparkinson Agents (pharmacology)</term><term>Cross-Over Studies</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Levodopa (pharmacology)</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (physiopathology)</term><term>Respiratory Function Tests</term><term>Respiratory Mechanics (drug effects)</term><term>Spirometry</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Airway Obstruction</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Respiratory Mechanics</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Cross-Over Studies</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Respiratory Function Tests</term><term>Spirometry</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Upper-airway obstruction (UAO) may be present in patients with Parkinson's disease (PD), and its reversibility after levodopa therapy has been suggested. To investigate the effects of oral intake of levodopa on pulmonary function and UAO criteria in patients with PD, we studied 22 patients with PD.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11171713</PMID><DateCreated><Year>2001</Year><Month>02</Month><Day>22</Day></DateCreated><DateCompleted><Year>2001</Year><Month>04</Month><Day>05</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0012-3692</ISSN><JournalIssue CitedMedium="Print"><Volume>119</Volume><Issue>2</Issue><PubDate><Year>2001</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Chest</Title><ISOAbbreviation>Chest</ISOAbbreviation></Journal><ArticleTitle>Effects of levodopa on pulmonary function in Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>387-93</MedlinePgn></Pagination><Abstract><AbstractText Label="STUDY OBJECTIVES" NlmCategory="OBJECTIVE">Upper-airway obstruction (UAO) may be present in patients with Parkinson's disease (PD), and its reversibility after levodopa therapy has been suggested. To investigate the effects of oral intake of levodopa on pulmonary function and UAO criteria in patients with PD, we studied 22 patients with PD.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Pulmonary function tests were performed after a 12-h withdrawal of levodopa therapy, and 1 h after oral intake of placebo or levodopa, according to a double-blind, placebo-controlled, crossover study. Six UAO criteria were recorded to detect UAO in patients. UAO was found in 5 of 21 patients on baseline conditions (1 patient could not perform all tests).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among the patients with UAO, after levodopa therapy three of five patients did not meet the four of six required criteria for defining UAO. Levodopa produced its effects on UAO criteria by means of a saw-tooth pattern improvement and/or a decrease below the defined thresholds of the peak inspiratory flow and the FEV(1)/peak expiratory flow (PEF) and FEV(1)/forced expiratory flow after 50% of the FVC (FEV(0.5)) ratios. Levodopa PEF increased by 0.85 L/s in patients with UAO and by 0.24 L/s in patients without UAO, while after placebo it increased by 0.03 L/s in patients with UAO and decreased by 0.16 L/s in patients without UAO (p = 0.02). Whereas in patients without UAO an increase of the FEV(1)/PEF and FEV(1)/FEV(0.5) ratios was observed after placebo and levodopa intake, these ratios decreased after levodopa and increased after placebo in patients with UAO.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These results show that levodopa administration in patients with PD induces significant variations in PEF and UAO ratios (FEV(1)/PEF and FEV(1)/FEV(0.5)).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Herer</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Service de Pneumologie, Centre Médical de Forcilles, Férolles-Attilly, France. HBherer@aol.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arnulf</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Housset</LastName><ForeName>B</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Chest</MedlineTA><NlmUniqueID>0231335</NlmUniqueID><ISSNLinking>0012-3692</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000402" MajorTopicYN="N">Airway Obstruction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012129" MajorTopicYN="N">Respiratory Function Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015656" MajorTopicYN="N">Respiratory Mechanics</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013147" MajorTopicYN="N">Spirometry</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>2</Month><Day>15</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>4</Month><Day>6</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>2</Month><Day>15</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11171713</ArticleId><ArticleId IdType="pii">S0012-3692(15)38212-X</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country></list><tree><noCountry><name sortKey="Arnulf, I" sort="Arnulf, I" uniqKey="Arnulf I" first="I" last="Arnulf">I. Arnulf</name><name sortKey="Housset, B" sort="Housset, B" uniqKey="Housset B" first="B" last="Housset">B. Housset</name></noCountry><country name="France"><noRegion><name sortKey="Herer, B" sort="Herer, B" uniqKey="Herer B" first="B" last="Herer">B. Herer</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000162 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000162 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:11171713
|texte= Effects of levodopa on pulmonary function in Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:11171713" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |